Case Report: Persistent severe thrombocytopenia after adjuvant ado-trastuzumab emtansine with sequential bone marrow findings and romiplostim support - Takeaways - MDSpire

Case Report: Persistent severe thrombocytopenia after adjuvant ado-trastuzumab emtansine with sequential bone marrow findings and romiplostim support

  • By

  • Dan Qiao

  • Lei Nie

  • Shuang Liu

  • Hai-bin Ding

  • June 17, 2026

  • 0 min

Share

  • 1

    Ado-trastuzumab emtansine (T-DM1) is an established adjuvant treatment for HER2-positive early breast cancer post-neoadjuvant therapy.

  • 2

    Severe, persistent thrombocytopenia is a rare but clinically challenging side effect of T-DM1, occurring in a subset of patients.

  • 3

    A 50-year-old woman developed sustained grade 4 thrombocytopenia after three cycles of T-DM1, refractory to standard treatments.

  • 4

    Sequential bone marrow evaluations indicated megakaryocytic maturation impairment without evidence of splenomegaly or clonal disease.

  • 5

    Romiplostim provided long-term stabilization of platelet counts, highlighting the need for individualized management in severe thrombocytopenia.

Original Source(s)

Case Report: Persistent severe thrombocytopenia after adjuvant ado-trastuzumab emtansine with sequential bone marrow findings and romiplostim support

  • by Dan Qiao, Lei Nie, Shuang Liu, Hai-bin Ding

  • June 17, 2026

Related Content

Endocrine therapy and thyroid function in early luminal breast cancer: a controlled longitudinal retrospective analysis

The long road after breast cancer: survivorship issues and long-term treatment effects in young women

Global research trends of TCM-based nonpharmacologic interventions in breast cancer supportive care: a bibliometric analysis (2000–2025)